

5.90.039

Section:	Prescription Drugs	Effective Date:	October 1, 2024
Subsection:	Topical Products	Original Policy Date:	January 1, 2020
Subject:	Topical Corticosteroids	Page:	1 of 24

Last Review Date: September 6, 2024

Topical Corticosteroids

Description

Alcovate Cream, Ointment 0.05% (alclometasone dipropionate)	Locoid Cream, Lipocream, Lotion, Ointment, Solution 0.1% (hydrocortisone butyrate)
Apexicon E Cream 0.05% (diflorasone diacetate)	Luxiq Foam 0.12% (betamethasone valerate)
Ala Scalp Lotion 2% (hydrocortisone)	Micort-HC Cream 2.5% (hydrocortisone acetate)
Capex Shampoo 0.01% (fluocinolone acetonide)	Nolix Cream, Lotion 0.05% (flurandrenolide)
Cloderm Cream 0.10% (clocortolone pivalate)	Olux Foam 0.05% Olux E Emulsion Foam 0.05% (clobetasol propionate)
Clobex Lotion, Shampoo, Spray 0.05% Clodan Shampoo 0.05% (clobetasol propionate)	Pandel Cream 0.1% (hydrocortisone probutate)
Cordran Cream 0.025% Cordran Cream, Lotion, Ointment 0.05% Cordran Tape 4mcg (flurandrenolide)	Psorcon Cream, Ointment 0.05% (diflorasone)
Cormax Solution 0.05% (clobetasol propionate)	Sernivo Spray 0.05% (betamethasone dipropionate)
Cutivate Cream, Lotion 0.05% Cutivate Ointment 0.005% (fluticasone propionate)	Synalar Cream, Ointment, Solution 0.01% Synalar Cream, Ointment 0.025% (fluocinolone acetonide)

5.90.039

Section: Prescription Drugs **Effective Date:** October 1, 2024
Subsection: Topical Products **Original Policy Date:** January 1, 2020
Subject: Topical Corticosteroids **Page:** 2 of 24

Cyclocort Cream, lotion, Ointment 0.1% (amcinonide)	Temovate-E Cream 0.05% Temovate Cream, Gel, Ointment, Solution 0.05% (clobetasol propionate)
Derma-smooth /FS body oil 0.01% Derma-smooth /FS scalp oil 0.01% (fluocinolone acetonide)	Texacort Solution 2.5% (hydrocortisone)
Dermatop Cream, Ointment 0.1% (prednicarbate)	Topicort Cream, Gel, Ointment, Spray 0.05% 0.25% (desoximetasone)
Desonate Gel 0.05% Desonide Cream Lotion, Ointment 0.05% Desowen Lotion 0.05% (desonide)	Triamcinolone Cream, Lotion, Ointment, Spray 0.025%, 0.05%, 0.1%, 0.5% Triderm Cream 0.1%, 0.5% Kenalog aerosol spray 0.147 mg/ml (triamcinolone acetonide)
Diprosone Cream, Lotion, Ointment 0.05% Diprolene AF Cream, Gel, Lotion, Ointment 0.05% (betamethasone dipropionate)	Tridesilon Cream 0.05% Verdeso Foam 0.05% (desonide)
Elocon Cream, Ointment, Solution 0.1% (mometasone furoate)	Trianex* Ointment 0.05% (triamcinolone acetonide)
Halog Cream, Ointment, Solution 0.1% (halcinonide)	Ultravate Cream, Lotion, Ointment 0.05% (halobetasol propionate)
Hydrocortisone Cream, Lotion, Ointment 1%, 2.5%	Wescort Cream, Ointment 0.2% (hydrocortisone valerate)
Impeklo Lotion 0.05% (clobetasol propionate)	Valisone Cream, Lotion, Ointment 0.01% (betamethasone valerate)
Impoyz Cream 0.025% (clobetasol propionate)	Vanos* Cream 0.1% (fluocinonide)
Lidex E Cream 0.05% Lidex Gel, Ointment, Solution, Cream 0.05% (fluocinonide)	Verdeso Foam 0.05% (desonide)

*Prior authorization for certain non-covered formulations applies only to formulary exceptions

Section:	Prescription Drugs	Effective Date:	October 1, 2024
Subsection:	Topical Products	Original Policy Date:	January 1, 2020
Subject:	Topical Corticosteroids	Page:	3 of 24

Background

The intent of the criteria is to provide coverage consistent with product labeling, FDA guidance, standards of medical practice, evidence-based drug information, and/or published guidelines. Pharmacy topical products have the potential for misuse. Misuse of these topical products not just over the face but also for any skin problem is quite common. It is very important to inform patients about the possible complications of these drugs and the extent of the problem because of irrational use of these drugs. The criteria was created in order to limit existing patients that have been taking doses above the FDA recommended limits and get them down to appropriate levels. This criteria is also intended to help prevent use of topical corticosteroids in topical foot baths (1-65).

Regulatory Status

FDA-approved indications: (1-65)

1. Alclometasone dipropionate, amcinonide, betamethasone dipropionate, betamethasone valerate, clobetasol propionate, clocortolone pivalate, desonide, desoximetasone, diflorasone diacetate, fluocinolone acetonide, fluocinonide, flurandrenolide, fluticasone propionate, halcinonide, halobetasol propionate, hydrocortisone, hydrocortisone acetate, hydrocortisone butyrate, hydrocortisone probutate, hydrocortisone valerate, mometasone furoate, prednicarbate, triamcinolone acetonide are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
2. Clobetasol Propionate Emollient Base Cream, Clobex Shampoo, Clobex Lotion, Clobex Spray, Derma-Smooth/FS (Scalp) Oil, Impoyz Cream, Olux Foam, Sernivo Spray, Topicort Spray, Ultravate Lotion are indicated for the treatment of psoriasis.
3. Cutivate Lotion, Derma-Smooth/FS (Body) Oil, Desonate Gel, Locoid Lipocream, Locoid Lotion, Verdeso Foam are indicated for the treatment of atopic dermatitis.
4. Capex Shampoo, Locoid Solution are indicated for the relief of the inflammatory and pruritic manifestations of seborrheic dermatitis.

The Pre-Prior Authorization (Pre-PA) allowance quantity limit for all topical corticosteroids (TCS) is based on the average American Academy of Dermatology (AAD) estimation for twice daily dosing over 9% body surface area (BSA) for acute treatment and for maintenance therapy,

Section:	Prescription Drugs	Effective Date:	October 1, 2024
Subsection:	Topical Products	Original Policy Date:	January 1, 2020
Subject:	Topical Corticosteroids	Page:	4 of 24

taking into consideration the available package sizes across the TCS class. The three month limit will be 460gm or 460mL per month, which is 3 times the one month limit (59-61). If the quantity requested exceeds the Pre-PA quantity limit, the claim will reject with a message indicating that a prior authorization is required.

The Prior-Authorization (PA) quantity limit for all topical corticosteroids (TCS) will be 240gm or 240mL per month which is based on the average AAD estimation for up to 18% BSA for acute treatment and for maintenance therapy, or for more frequent dosing (up to four times daily) or longer duration of treatment, taking into consideration the available package sizes. The three month limit will be 720gm or 720mL (59-61).

No universal standard exists for quantity of application, although suggested methods include use of the adult fingertip unit (the amount from the distal interphalangeal joint to the fingertip, or approximately 0.5 grams (gm), being applied over an area equal to 2 adult palms), following the rule of 9's that measures the percent affected area, and use of charts that propose amounts based on patient age and body site (59-61).

In adults, the rule of nines is used as a rough indicator of % BSA. Palmar hand surface is approximately 1% BSA (59-61):

Anatomic Surface	% of Body Surface
head and neck	9%
anterior trunk	18%
posterior trunk	18%
arms, including hands	9% each
legs, including feet	18% each
genitalia	1%

Quantity for 1% BSA, suggested AAD estimation:

- Grams per application:
 - 0.5gm per application over 2 palms (1% BSA per palm) = 0.25gm per application over 1% BSA
- Applications per month:
 - For a month supply, at 2 weeks acute daily treatment (14 days) and maintenance twice weekly (or gradual reduction) (6 days) therapy at 2 applications per day = (14+6) days x 2 per day = 40 applications per month
- Grams per month for 1% BSA:

Section:	Prescription Drugs	Effective Date:	October 1, 2024
Subsection:	Topical Products	Original Policy Date:	January 1, 2020
Subject:	Topical Corticosteroids	Page:	5 of 24

- At 0.25gm per application over 1% BSA x 40 applications per month = 0.25gm x 40 = 10gm per 1% BSA per month

Since manufacturer package sizes may vary, it is the discretion of the dispensing pharmacy to fill quantities up to these quantity limits. In such cases the filling limit and day supply may be less than what is indicated. For example, Pandel is available as an 80gm tube, the initial limit is set at 460gm as a 90 day supply, therefore if dispensed as 240gm this may be considered less than a 90 day supply (59-65).

Related policies

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

The topical products included in this policy may be considered **medically necessary** if the conditions indicated below are met.

The topical products included in this policy may be considered **investigational** for all other indications.

Prior-Approval Requirements

Diagnosis

Patient must have the following:

1. FDA-approved indication supporting the use of topical product
2. Requested medication is **NOT** being used in a footbath

Prior – Approval *Renewal* Requirements

Same as above

Policy Guidelines

Section: Prescription Drugs	Effective Date: October 1, 2024
Subsection: Topical Products	Original Policy Date: January 1, 2020
Subject: Topical Corticosteroids	Page: 6 of 24

Pre - PA Allowance

Quantity

*Ingredient	Product Name	Strength	UOM	Potency	3 MONTH LIMIT
ALCLOMETASONE DIPROPIONATE	ALCLOMETASONE CREAM	0.05%	GM	Low to Medium	460
	ALCLOMETASONE OINTMENT	0.05%	GM	Low to Medium	
*Ingredient	Product Name	Strength	UOM	Potency	3 MONTH LIMIT
AMCINONIDE	AMCINONIDE CREAM	0.1%	GM	High	460
	AMCINONIDE LOTION	0.1%	ML	High	
	AMCINONIDE OINTMENT	0.1%	GM	High	
*Ingredient	Product Name	Strength	UOM	Potency	3 MONTH LIMIT
BETAMETHASONE DIPROPIONATE	SERNIVO SPRAY	0.05%	ML	Medium	460
	BETAMETHASONE DIPROPIONATE CREAM	0.05%	GM	Medium	
	BETAMETHASONE DIPROPIONATE LOTION	0.05%	ML	Medium	
	BETAMETHASONE DIPROPIONATE OINTMENT	0.05%	GM	Very high	
	DIPROLENE AF AUGMENTED CREAM	0.05%	GM	High	
	BETAMETHASONE DIPROPIONATE AUGMENTED CREAM	0.05%	GM		
	BETAMETAMETHASONE DIPROPIONATE AUGMENTED GEL	0.05%	GM	Very high	
	BETAMETAMETHASONE DIPROPIONATE AUGMENTED LOTION	0.05%	ML	Very high	
	DIPROLENE AUGMENTED OINTMENT	0.05%	GM	Very high	
	BETAMETHASONE DIPROPIONATE AUGMENTED OINTMENT	0.05%	GM		
*Ingredient	Product Name	Strength	UOM	Potency	3 MONTH LIMIT

5.90.039

Section: Prescription Drugs	Effective Date: October 1, 2024
Subsection: Topical Products	Original Policy Date: January 1, 2020
Subject: Topical Corticosteroids	Page: 7 of 24

BETAMETHASONE VALERATE	BETAMETHASONE VALERATE CREAM	0.1%	GM	Medium	460
	LUXIQ AEROSOL FOAM	0.12%	GM	Medium	
	BETAMETHASONE VALERATE AEROSOL FOAM	0.12%	GM		
	BETAMETHASONE VALERATE LOTION	0.1%	ML	Medium	
	BETAMETHASONE VALERATE OINTMENT	0.1%	GM	Medium	
*Ingredient	Product Name	Strength	UOM	Potency	3 MONTH LIMIT
CLOBETASOL PROPIONATE	CLOBEX SPRAY	0.05%	ML	Very high	460
	CLOBETASOL SPRAY	0.05%	ML		
	CLOBETASOL SOLUTION	0.05%	ML	High	
	CORMAX SOLUTION	0.05%	ML		
	TEMOVATE SOLUTION	0.05%	ML		
	IMPOYZ CREAM	0.025%	GM	High	
	TEMOVATE CREAM	0.05%	GM	Very high	
	CLOBETASOL CREAM	0.05%	GM		
	OLUX AEROSOL FOAM	0.05%	GM	Very high	
	CLOBETASOL AEROSOL FOAM	0.05%	GM		
	CLOBETASOL GEL	0.05%	GM	Very high	
	CLOBEX LOTION	0.05%	ML	Very high	
	CLOBETASOL LOTION	0.05%	ML		
	TEMOVATE OINTMENT	0.05%	GM	Very high	
	CLOBETASOL OINTMENT	0.05%	GM		
	CLOBEX SHAMPOO	0.05%	ML	Very high	
	CLODAN SHAMPOO	0.05%	ML		
	CLOBETASOL E EMOLLIENT CREAM	0.05%	GM	Very high	

5.90.039

Section: Prescription Drugs	Effective Date: October 1, 2024
Subsection: Topical Products	Original Policy Date: January 1, 2020
Subject: Topical Corticosteroids	Page: 8 of 24

	OLUX-E AEROSOL EMULSION FOAM	0.05%	GM	Very high	
	CLOBETASOL AEROSOL EMULSION FOAM	0.05%	GM		
	IMPEKLO LOTION	0.05%	GM	Very high	
*Ingredient	Product Name	Strength	UOM	Potency	3 MONTH LIMIT
CLOCORTOLONE PIVALATE	CLODERM CREAM	0.10%	GM	Medium	460
	CLOCORTOLONE CREAM	0.10%	GM		
*Ingredient	Product Name	Strength	UOM	Potency	3 MONTH LIMIT
DESONIDE	DESOWEN CREAM	0.05%	GM	Low to Medium	460
	DESONIDE CREAM	0.05%	GM		
	TRIDESILON CREAM	0.05%	GM	Low	
	DESONIDE CREAM	0.05%	GM		
	VERDESO AEROSOL FOAM	0.05%	GM	Low	
	DESONATE GEL	0.05%	GM	Low	
	DESOWEN LOTION	0.05%	ML	Low to Medium	
	DESONIDE LOTION	0.05%	ML		
	DESONIDE OINTMENT	0.05%	GM	Low	
*Ingredient	Product Name	Strength	UOM	Potency	3 MONTH LIMIT
DESOXIMETASONE	TOPICORT SPRAY	0.25%	ML	High to Very high	460
	DESOXIMETASONE SPRAY	0.25%	ML		
	TOPICORT CREAM	0.05%	GM	Medium	
	DESOXIMETASONE CREAM	0.05%	GM		
	TOPICORT CREAM	0.25%	GM	High	
	DESOXIMETASONE CREAM	0.25%	GM		
	TOPICORT GEL	0.05%	GM	High	

5.90.039

Section: Prescription Drugs	Effective Date: October 1, 2024
Subsection: Topical Products	Original Policy Date: January 1, 2020
Subject: Topical Corticosteroids	Page: 9 of 24

	DESOXIMETASONE GEL	0.05%	GM	High	
	TOPICORT OINTMENT	0.05%	GM		
	DESOXIMETASONE OINTMENT	0.05%	GM		
	TOPICORT OINTMENT	0.25%	GM	High	
	DESOXIMETASONE OINTMENT	0.25%	GM		
*Ingredient	Product Name	Strength	UOM	Potency	3 MONTH LIMIT
DIFLORASONE DIACETATE	PSORCON CREAM	0.05%	GM	High	460
	DIFLORASONE CREAM	0.05%	GM		
	DIFLORASONE OINTMENT	0.05%	GM	Very high	
	APEXICON E CREAM	0.05%	GM	High	
*Ingredient	Product Name	Strength	UOM	Potency	3 MONTH LIMIT
FLUOCINOLONE ACETONIDE	DERMA-SMOOTH /FS BODY OIL	0.01%	ML	Low to Medium	460
	FLUOCINOLONE BODY OIL	0.01%	ML		
	DERMA-SMOOTH /FS SCALP OIL	0.01%	ML	Low to Medium	
	FLUOCINOLONE SCALP OIL	0.01%	ML		
	SYNALAR SOLUTION	0.01%	ML	Low	
	FLUOCINOLONE SOLUTION	0.01%	ML		
	FLUOCINOLONE CREAM	0.01%	GM	Low	
	SYNALAR CREAM	0.025%	GM	Medium	
	FLUOCINOLONE CREAM	0.025%	GM		
	SYNALAR OINTMENT	0.025%	GM	Medium	
	FLUOCINOLONE OINTMENT	0.025%	GM		
	CAPEX SHAMPOO	0.01%	ML	Low to Medium	
*Ingredient	Product Name	Strength	UOM	Potency	3 MONTH LIMIT

5.90.039

Section: Prescription Drugs	Effective Date: October 1, 2024
Subsection: Topical Products	Original Policy Date: January 1, 2020
Subject: Topical Corticosteroids	Page: 10 of 24

FLUOCINONIDE	FLUOCINONIDE SOLUTION	0.05%	ML	High	460
	FLUOCINONIDE CREAM	0.05%	GM	High	
	FLUOCINONIDE GEL	0.05%	GM	High	
	FLUOCINONIDE OINTMENT	0.05%	GM	High	
	FLUOCINONIDE-E EMULSIFIED CREAM	0.05%	GM	High	
	FLUOCINONIDE CREAM	0.1%	GM	Very high	
	VANOS CREAM	0.1%	GM	Very high	None
*Ingredient	Product Name	Strength	UOM	Potency	3 MONTH LIMIT
FLURANDRENOLIDE	CORDRAN CREAM	0.025%	GM	High	460
	CORDRAN CREAM	0.05%	GM	High	
	NOLIX CREAM	0.05%	GM	High	
	CORDRAN LOTION	0.05%	ML	High	
	NOLIX LOTION	0.05%	ML	High	
	CORDRAN OINTMENT	0.05%	GM	High	
	FLURANDRENOLIDE OINTMENT	0.05%	GM	High	
*Ingredient	Product Name	Strength	UOM	Potency	3 MONTH LIMIT
FLURANDRENOLIDE	CORDRAN TAPE	4 MCG	EA	High	2 Rolls
*Ingredient	Product Name	Strength	UOM	Potency	3 MONTH LIMIT
FLUTICASONE PROPIONATE	FLUTICASONE CREAM	0.05%	GM	Medium	460
	CUTIVATE LOTION	0.05%	ML	Medium	
	FLUTICASONE LOTION	0.05%	ML	Medium	
	FLUTICASONE OINTMENT	0.005%	GM	Medium	
*Ingredient	Product Name	Strength	UOM	Potency	3 MONTH LIMIT
HALCINONIDE	HALOG CREAM	0.1%	GM	High	460

5.90.039

Section: Prescription Drugs	Effective Date: October 1, 2024
Subsection: Topical Products	Original Policy Date: January 1, 2020
Subject: Topical Corticosteroids	Page: 11 of 24

	HALOG OINTMENT	0.1%	GM	High	
	HALOG SOLUTION	0.1%	ML	High	
*Ingredient	Product Name	Strength	UOM	Potency	3 MONTH LIMIT
HALOBETASOL PROPIONATE	ULTRAVATE CREAM	0.05%	GM	Very high	460
	HALOBETASOL CREAM	0.05%	GM		
	ULTRAVATE LOTION	0.05%	ML	Very high	
	ULTRAVATE OINTMENT	0.05%	GM	Very high	
	HALOBETASOL OINTMENT	0.05%	GM		
*Ingredient	Product Name	Strength	UOM	Potency	3 MONTH LIMIT
HYDROCORTISONE	TEXACORT SOLUTION	2.5%	ML	Low	460
	HYDROCORTISONE CREAM	1%	GM	Low	
	HYDROCORTISONE CREAM	2.5%	GM	Low	
	ALA SCALP LOTION	2%	ML	Low	
	HYDROCORTISONE LOTION	2.5%	ML	Low	
	HYDROCORTISONE OINTMENT	1%	GM	Low	
	HYDROCORTISONE OINTMENT	2.5%	GM	Low	
*Ingredient	Product Name	Strength	UOM	Potency	3 MONTH LIMIT
HYDROCORTISONE ACETATE	MICORT-HC CREAM	2.5%	GM	Low	460
*Ingredient	Product Name	Strength	UOM	Potency	3 MONTH LIMIT
HYDROCORTISONE VALERATE	HYDROCORTISONE VALERATE CREAM	0.2%	GM	Medium	460
	WESTCORT OINTMENT	0.2%	GM	Medium	
	HYDROCORTISONE VALERATE OINTMENT	0.2%	GM		
*Ingredient	Product Name	Strength	UOM	Potency	3 MONTH LIMIT
HYDROCORTISONE PROBUTATE	PANDEL CREAM	0.1%	GM	Medium	460

Section: Prescription Drugs	Effective Date: October 1, 2024
Subsection: Topical Products	Original Policy Date: January 1, 2020
Subject: Topical Corticosteroids	Page: 12 of 24

*Ingredient	Product Name	Strength	UOM	Potency	3 MONTH LIMIT
HYDROCORTISONE BUTYRATE	LOCOID SOLUTION	0.1%	ML	Medium	460
	HYDROCORTISONE BUTYRATE SOLUTION	0.10%	ML		
	LOCOID CREAM	0.1%	GM	Medium	
	HYDROCORTISONE BUTYRATE CREAM	0.1%	GM		
	LOCOID LOTION	0.1%	ML	Medium	
	HYDROCORTISONE LOTION	0.1%	ML		
	LOCOID OINTMENT	0.1%	GM	Medium	
	HYDROCORTISONE BUTYRATE OINTMENT	0.1%	GM		
	LOCOID HYDROPHILIC LIPOCREAM	0.1%	GM	Medium	
	HYDROCORTISONE BUTYRATE HYDROPHILIC LIPOCREAM	0.10%	GM		
*Ingredient	Product Name	Strength	UOM	Potency	3 MONTH LIMIT
MOMETASONE FUROATE	MOMETASONE SOLUTION	0.1%	ML	Medium	460
	ELOCON CREAM	0.1%	GM	Medium	
	MOMETASONE CREAM	0.1%	GM		
	ELOCON OINTMENT	0.1%	GM	Medium	
	MOMETASONE OINTMENT	0.1%	GM		
*Ingredient	Product Name	Strength	UOM	Potency	3 MONTH LIMIT
PREDNICARBATE	PREDNICARBATE CREAM	0.1%	GM	Medium	460
	DERMATOP OINTMENT	0.1%	GM	Medium	
	PREDNICARBATE OINTMENT	0.1%	GM		
*Ingredient	Product Name	Strength	UOM	Potency	3 MONTH LIMIT
TRIAMCINOLONE ACETONIDE	KENALOG AEROSOL SPRAY	SPRAY	GM	High	460
	TRIAMCINOLONE AEROSOL SPRAY	SPRAY	GM		

5.90.039

Section: Prescription Drugs **Effective Date:** October 1, 2024
Subsection: Topical Products **Original Policy Date:** January 1, 2020
Subject: Topical Corticosteroids **Page:** 13 of 24

	TRIAMCINOLONE CREAM	0.025%	GM	Medium	
	TRIAMCINOLONE CREAM	0.1%	GM	Medium	
	TRIAMCINOLONE CREAM	0.5%	GM	High	
	TRIAMCINOLONE LOTION	0.025%	ML	Medium	
	TRIAMCINOLONE LOTION	0.1%	ML	Medium	
	TRIAMCINOLONE OINTMENT	0.025%	GM	Medium	
	TRIAMCINOLONE OINTMENT	0.1%	GM	Medium	
	TRIAMCINOLONE OINTMENT	0.5%	GM	High	
	TRIANEX OINTMENT	0.05%	GM	Medium	None

➤ Pre-PA quantity limit allows for the American Academy of Dermatology (AAD) recommended dosage.
 ➤ Patients are allowed Pre-PA for each *ingredient listed above (apart from noted exceptions).
 ➤ If the quantity requested exceeds the Pre-PA quantity limits, the claim will reject with a message indicating that a prior authorization is required.

Prior - Approval Limits

Quantity

*Ingredient	Product Name	Strength	UOM	Potency	Quantity per 90 Days
ALCLOMETASONE DIPROPIONATE	ALCLOMETASONE CREAM	0.05%	GM	Low to Medium	720
	ALCLOMETASONE OINTMENT	0.05%	GM	Low to Medium	
*Ingredient	Product Name	Strength	UOM	Potency	Quantity per 90 Days
AMCINONIDE	AMCINONIDE CREAM	0.1%	GM	High	720
	AMCINONIDE LOTION	0.1%	ML	High	
	AMCINONIDE OINTMENT	0.1%	GM	High	
*Ingredient	Product Name	Strength	UOM	Potency	Quantity per 90 Days
BETAMETHASONE DIPROPIONATE	SERNIVO SPRAY	0.05%	ML	Medium	720

5.90.039

Section: Prescription Drugs	Effective Date: October 1, 2024
Subsection: Topical Products	Original Policy Date: January 1, 2020
Subject: Topical Corticosteroids	Page: 14 of 24

	BETAMETHASONE DIPROPIONATE CREAM	0.05%	GM	Medium	
	BETAMETHASONE DIPROPIONATE LOTION	0.05%	ML	Medium	
	BETAMETHASONE DIPROPIONATE OINTMENT	0.05%	GM	Very high	
	DIPROLENE AF AUGMENTED CREAM	0.05%	GM	High	
	BETAMETHASONE DIPROPIONATE AUGMENTED CREAM	0.05%	GM		
	BETAMETAMETHASONE DIPROPIONATE AUGMENTED GEL	0.05%	GM	Very high	
	BETAMETAMETHASONE DIPROPIONATE AUGMENTED LOTION	0.05%	ML	Very high	
	DIPROLENE AUGMENTED OINTMENT	0.05%	GM	Very high	
	BETAMETHASONE DIPROPIONATE AUGMENTED OINTMENT	0.05%	GM		
	*Ingredient	Product Name	Strength	UOM	
BETAMETHASONE VALERATE	BETAMETHASONE VALERATE CREAM	0.1%	GM	Medium	720
	LUXIQ AEROSOL FOAM	0.12%	GM	Medium	
	BETAMETHASONE VALERATE AEROSOL FOAM	0.12%	GM		
	BETAMETHASONE VALERATE LOTION	0.1%	ML	Medium	
	BETAMETHASONE VALERATE OINTMENT	0.1%	GM	Medium	
*Ingredient	Product Name	Strength	UOM	Potency	Quantity per 90 Days
CLOBETASOL PROPIONATE	CLOBEX SPRAY	0.05%	ML	Very high	
	CLOBETASOL SPRAY	0.05%	ML		
	CLOBETASOL SOLUTION	0.05%	ML	High	
	CORMAX SOLUTION	0.05%	ML		
	TEMOVATE SOLUTION	0.05%	ML		

5.90.039

Section: Prescription Drugs	Effective Date: October 1, 2024
Subsection: Topical Products	Original Policy Date: January 1, 2020
Subject: Topical Corticosteroids	Page: 15 of 24

	IMPOYZ CREAM	0.025%	GM	High	720
	TEMOVATE CREAM	0.05%	GM	Very high	
	CLOBETASOL CREAM	0.05%	GM		
	OLUX AEROSOL FOAM	0.05%	GM	Very high	
	CLOBETASOL AEROSOL FOAM	0.05%	GM		
	CLOBETASOL GEL	0.05%	GM	Very high	
	CLOBEX LOTION	0.05%	ML	Very high	
	CLOBETASOL LOTION	0.05%	ML		
	TEMOVATE OINTMENT	0.05%	GM	Very high	
	CLOBETASOL OINTMENT	0.05%	GM		
	CLOBEX SHAMPOO	0.05%	ML	Very high	
	CLODAN SHAMPOO	0.05%	ML		
	CLOBETASOL E EMOLLIENT CREAM	0.05%	GM	Very high	
	OLUX-E AEROSOL EMULSION FOAM	0.05%	GM	Very high	
	CLOBETASOL AEROSOL EMULSION FOAM	0.05%	GM		
	IMPEKLO LOTION	0.05%	GM	Very high	
*Ingredient	Product Name	Strength	UOM	Potency	Quantity per 90 Days
CLOCORTOLONE PIVALATE	CLODERM CREAM	0.10%	GM	Medium	720
	CLOCORTOLONE CREAM	0.10%	GM		
*Ingredient	Product Name	Strength	UOM	Potency	Quantity per 90 Days
DESONIDE	DESOWEN CREAM	0.05%	GM	Low to Medium	
	DESONIDE CREAM	0.05%	GM		
	TRIDESILON CREAM	0.05%	GM	Low	
	DESONIDE CREAM	0.05%	GM		

5.90.039

Section:	Prescription Drugs	Effective Date:	October 1, 2024
Subsection:	Topical Products	Original Policy Date:	January 1, 2020
Subject:	Topical Corticosteroids	Page:	16 of 24

	VERDESO AEROSOL FOAM	0.05%	GM	Low	720
	DESONATE GEL	0.05%	GM	Low	
	DESOWEN LOTION	0.05%	ML	Low to Medium	
	DESONIDE LOTION	0.05%	ML		
	DESONIDE OINTMENT	0.05%	GM	Low	
*Ingredient	Product Name	Strength	UOM	Potency	Quantity per 90 Days
DESOXIMETASONE	TOPICORT SPRAY	0.25%	ML	High to very high	720
	DESOXIMETASONE SPRAY	0.25%	ML		
	TOPICORT CREAM	0.05%	GM	Medium	
	DESOXIMETASONE CREAM	0.05%	GM		
	TOPICORT CREAM	0.25%	GM	High	
	DESOXIMETASONE CREAM	0.25%	GM		
	TOPICORT GEL	0.05%	GM	High	
	DESOXIMETASONE GEL	0.05%	GM		
	TOPICORT OINTMENT	0.05%	GM	High	
	DESOXIMETASONE OINTMENT	0.05%	GM		
	TOPICORT OINTMENT	0.25%	GM	High	
	DESOXIMETASONE OINTMENT	0.25%	GM		
*Ingredient	Product Name	Strength	UOM	Potency	Quantity per 90 Days
DIFLORASONE DIACETATE	PSORCON CREAM	0.05%	GM	High	720
	DIFLORASONE CREAM	0.05%	GM		
	DIFLORASONE OINTMENT	0.05%	GM	Very high	
	APEXICON E CREAM	0.05%	GM	High	
*Ingredient	Product Name	Strength	UOM	Potency	Quantity per 90 Days

5.90.039

Section: Prescription Drugs	Effective Date: October 1, 2024
Subsection: Topical Products	Original Policy Date: January 1, 2020
Subject: Topical Corticosteroids	Page: 17 of 24

FLUOCINOLONE ACETONIDE	DERMA-SMOOTH /FS BODY OIL	0.01%	ML	Low to medium	720
	FLUOCINOLONE BODY OIL	0.01%	ML		
	DERMA-SMOOTH /FS SCALP OIL	0.01%	ML	Low to medium	
	FLUOCINOLONE SCALP OIL	0.01%	ML		
	SYNALAR SOLUTION	0.01%	ML	Low	
	FLUOCINOLONE SOLUTION	0.01%	ML		
	FLUOCINOLONE CREAM	0.01%	GM	Low	
	SYNALAR CREAM	0.025%	GM	Medium	
	FLUOCINOLONE CREAM	0.025%	GM		
	SYNALAR OINTMENT	0.025%	GM	Medium	
	FLUOCINOLONE OINTMENT	0.025%	GM		
	CAPEX SHAMPOO	0.01%	ML	Low to Medium	
*Ingredient	Product Name	Strength	UOM	Potency	Quantity per 90 Days
FLUOCINONIDE	FLUOCINONIDE SOLUTION	0.05%	ML	High	720
	FLUOCINONIDE CREAM	0.05%	GM	High	
	FLUOCINONIDE GEL	0.05%	GM	High	
	FLUOCINONIDE OINTMENT	0.05%	GM	High	
	FLUOCINONIDE-E EMULSIFIED CREAM	0.05%	GM	High	
	FLUOCINONIDE CREAM	0.1%	GM	Very high	
	VANOS CREAM	0.1%	GM	Very high	Refer to the Formulary Exception Table Below
*Ingredient	Product Name	Strength	UOM	Potency	Quantity per 90 Days
FLURANDRENOLIDE	CORDRAN CREAM	0.025%	GM	High	720
	CORDRAN CREAM	0.05%	GM	High	
	NOLIX CREAM	0.05%	GM		

5.90.039

Section: Prescription Drugs	Effective Date: October 1, 2024
Subsection: Topical Products	Original Policy Date: January 1, 2020
Subject: Topical Corticosteroids	Page: 18 of 24

	CORDRAN LOTION	0.05%	ML	High	
	NOLIX LOTION	0.05%	ML		
	CORDRAN OINTMENT	0.05%	GM	High	
	FLURANDRENOLIDE OINTMENT	0.05%	GM		
*Ingredient	Product Name	Strength	UOM	Potency	Quantity per 90 Days
FLURANDRENOLIDE	CORDRAN TAPE	4 MCG	EA	High	4 Rolls
*Ingredient	Product Name	Strength	UOM	Potency	Quantity per 90 Days
FLUTICASONE PROPIONATE	FLUTICASONE CREAM	0.05%	GM	Medium	720
	CUTIVATE LOTION	0.05%	ML	Medium	
	FLUTICASONE LOTION	0.05%	ML		
	FLUTICASONE OINTMENT	0.005%	GM	Medium	
*Ingredient	Product Name	Strength	UOM	Potency	Quantity per 90 Days
HALCINONIDE	HALOG CREAM	0.1%	GM	High	720
	HALOG OINTMENT	0.1%	GM	High	
	HALOG SOLUTION	0.1%	ML	High	
*Ingredient	Product Name	Strength	UOM	Potency	Quantity per 90 Days
HALOBETASOL PROPIONATE	ULTRAVATE CREAM	0.05%	GM	Very high	720
	HALOBETASOL CREAM	0.05%	GM		
	ULTRAVATE LOTION	0.05%	ML	Very high	
	ULTRAVATE OINTMENT	0.05%	GM	Very high	
	HALOBETASOL OINTMENT	0.05%	GM		
*Ingredient	Product Name	Strength	UOM	Potency	Quantity per 90 Days
HYDROCORTISONE	TEXACORT SOLUTION	2.5%	ML	Low	720
	HYDROCORTISONE CREAM	1%	GM	Low	

5.90.039

Section: Prescription Drugs	Effective Date: October 1, 2024
Subsection: Topical Products	Original Policy Date: January 1, 2020
Subject: Topical Corticosteroids	Page: 19 of 24

	HYDROCORTISONE CREAM	2.5%	GM	Low	
	ALA SCALP LOTION	2%	ML	Low	
	HYDROCORTISONE LOTION	2.5%	ML	Low	
	HYDROCORTISONE OINTMENT	1%	GM	Low	
	HYDROCORTISONE OINTMENT	2.5%	GM	Low	
*Ingredient	Product Name	Strength	UOM	Potency	Quantity per 90 Days
HYDROCORTISONE ACETATE	MICORT-HC CREAM	2.5%	GM	Low	720
*Ingredient	Product Name	Strength	UOM	Potency	Quantity per 90 Days
HYDROCORTISONE VALERATE	HYDROCORTISONE VALERATE CREAM	0.2%	GM	Medium	720
	WESTCORT OINTMENT	0.2%	GM	Medium	
	HYDROCORTISONE VALERATE OINTMENT	0.2%	GM		
*Ingredient	Product Name	Strength	UOM	Potency	Quantity per 90 Days
HYDROCORTISONE PROBUTATE	PANDEL CREAM	0.1%	GM	Medium	720
*Ingredient	Product Name	Strength	UOM	Potency	Quantity per 90 Days
HYDROCORTISONE BUTYRATE	LOCOID SOLUTION	0.1%	ML	Medium	720
	HYDROCORTISONE BUTYRATE SOLUTION	0.10%	ML		
	LOCOID CREAM	0.1%	GM	Medium	
	HYDROCORTISONE BUTYRATE CREAM	0.1%	GM		
	LOCOID LOTION	0.1%	ML	Medium	
	HYDROCORTISONE LOTION	0.1%	ML		
	LOCOID OINTMENT	0.1%	GM	Medium	
	HYDROCORTISONE BUTYRATE OINTMENT	0.1%	GM		
	LOCOID HYDROPHILIC LIPOCREAM	0.1%	GM		

5.90.039

Section: Prescription Drugs	Effective Date: October 1, 2024
Subsection: Topical Products	Original Policy Date: January 1, 2020
Subject: Topical Corticosteroids	Page: 20 of 24

*Ingredient	Product Name	Strength	UOM	Potency	Quantity per 90 Days
	HYDROCORTISONE BUTYRATE HYDROPHILIC LIPOCREAM	0.10%	GM		
MOMETASONE FUROATE	MOMETASONE SOLUTION	0.1%	ML	Medium	720
	ELOCON CREAM	0.1%	GM	Medium	
	MOMETASONE CREAM	0.1%	GM		
	ELOCON OINTMENT	0.1%	GM	Medium	
	MOMETASONE OINTMENT	0.1%	GM		
*Ingredient	Product Name	Strength	UOM	Potency	Quantity per 90 Days
PREDNICARBATE	PREDNICARBATE CREAM	0.1%	GM	Medium	720
	DERMATOP OINTMENT	0.1%	GM	Medium	
	PREDNICARBATE OINTMENT	0.1%	GM		
*Ingredient	Product Name	Strength	UOM	Potency	Quantity per 90 Days
TRIAMCINOLONE ACETONIDE	KENALOG AEROSOL SPRAY	SPRAY	GM	High	720
	TRIAMCINOLONE AEROSOL SPRAY	SPRAY	GM		
	TRIAMCINOLONE CREAM	0.025%	GM	Medium	
	TRIAMCINOLONE CREAM	0.1%	GM	Medium	
	TRIAMCINOLONE CREAM	0.5%	GM	High	
	TRIAMCINOLONE LOTION	0.025%	ML	Medium	
	TRIAMCINOLONE LOTION	0.1%	ML	Medium	
	TRIAMCINOLONE OINTMENT	0.025%	GM	Medium	
	TRIAMCINOLONE OINTMENT	0.1%	GM	Medium	
	TRIAMCINOLONE OINTMENT	0.5%	GM	High	
	TRIANEX OINTMENT	0.05%	GM	Medium	

- The Prior-Approval quantity limit is based on average AAD estimation for up to 18% BSA.
- Eligible patients are allowed a PA for each requested *ingredient listed above.

5.90.039

Section:	Prescription Drugs	Effective Date:	October 1, 2024
Subsection:	Topical Products	Original Policy Date:	January 1, 2020
Subject:	Topical Corticosteroids	Page:	21 of 24

*Ingredient	Medication <u>with Approved Formulary Exception Only</u>	Strength	UOM	Potency	Quantity per 90 Days
TRIAMCINOLONE ACETONIDE	TRIANEX OINTMENT	0.05%	GM	Medium	460
FLUOCINONIDE	VANOS CREAM	0.1%	GM	Very high	460

➤ The Prior-Approval quantity limit with approved formulary exception allows for the American Academy of Dermatology (AAD) recommended dosage.

➤ Eligible patients are allowed a PA for each requested *ingredient listed above.

Duration 6 months

Prior-Approval *Renewal* Limits

Same as above

Rationale

Summary

The criteria was created in order to limit existing patients that have been taking doses above the American Academy of Dermatology (AAD) recommended limits and get them down to appropriate levels. This will help eliminate inappropriate use of these medications while still providing adequate relief to patients (1-65).

Prior authorization is required to ensure the safe, clinically appropriate, and cost-effective use of the topical products included in this policy while maintaining optimal therapeutic outcomes.

References

1. Ala Scalp Lotion [package insert]. Johnson City, TN: Crown Laboratories, Inc.; May 2017.
2. Alclometasone Ointment [package insert]. Hawthorne, NY: Taro Pharmaceuticals Inc.; January 2017.
3. Amcinonide Cream [package insert]. Melville, NY: Fougera Pharmaceuticals Inc.; August 2012.
4. ApexiCon E Cream [package insert]. Melville, NY: PharmaDerm; October 2018.
5. Betamethasone Dipropionate Cream [package insert]. South Plainfield, NJ: G&W Laboratories, Inc.; June 2015.

Section:	Prescription Drugs	Effective Date:	October 1, 2024
Subsection:	Topical Products	Original Policy Date:	January 1, 2020
Subject:	Topical Corticosteroids	Page:	22 of 24

6. Betamethasone Dipropionate Ointment [package insert]. Buena, New Jersey: Teligent Pharma, Inc.; September 2017.
7. Betamethasone Dipropionate Augmented Lotion [package insert]. Melville, NY: Fougera Pharmaceuticals Inc.; May 2018.
8. Betamethasone Valerate Lotion [package insert]. Newtown, PA: STI Pharma LLC; July 2017.
9. Capex Shampoo [package insert]. Fort Worth, Texas: Galderma Laboratories, L.P.; December 2015.
10. Clobetasol Propionate Emollient Base Cream [package insert]. Melville, New York: Fougera Pharmaceuticals Inc., September 2016.
11. Clobex Spray [package insert]. Fort Worth, TX: Galderma Laboratories, L.P.; January 2019.
12. Cloderm Cream [package insert]. San Antonio, TX: DPT Laboratories; June 2017.
13. Cordran Cream, Ointment [package insert]. San Antonio, TX: DPT Laboratories; May 2017.
14. Cutivate Lotion [package insert]. Melville, NY: PharmaDerm; July 2015.
15. Derma-Smoothe/FS Body Oil [package insert]. Sanford, FL: Hill Dermaceuticals, Inc.; October 2013.
16. Derma-Smoothe/FS Scalp Oil [package insert]. Sanford, FL: Hill Dermaceuticals, Inc.; January 2014.
17. Dermatop Ointment [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; November 2012.
18. Desonate Gel [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; July 2014.
19. Desonide Ointment [package insert]. Hawthorne, NY: Taro Pharmaceuticals U.S.A., Inc.; October 2015.
20. DesOwen Cream, Lotion [package insert]. Fort Worth, TX: Galderma; May 2014.
21. Diflorasone Diacetate Ointment [package insert]. Melville, NY: E. Fougera & CO.; July 2018. July 2013.
22. Diprolene Ointment [package insert]. Whitehouse Station, NJ: Merck Sharp and Dohme Corp.; March 2018.
23. Diprolene AF Cream [package insert]. Whitehouse Station, NJ: Merck Sharp and Dohme Corp.; March 2018.
24. Elocon Cream [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp; May 2018.
25. Fluocinonide Cream 0.05%, Gel, Ointment, Emulsified Base Cream [package insert]. Hawthorne, NY: Taro Pharmaceuticals U.S.A., Inc.; November 2017.
26. Fluticasone Propionate Cream [package insert]. South Plainfield, NJ: G&W Laboratories, Inc.; May 2015.
27. Halog Cream [package insert]. San Antonio TX: DPT Laboratories, Inc.; May 2018.
28. Halog Solution [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; March 2020.
29. Hydrocortisone Cream 1% [package insert]. Johnson City, TN: Crown Laboratories, Inc; December 2017.
30. Hydrocortisone Cream 2.5%, Ointment 2.5% [package insert]. Bronx, NY; Perrigo; August 2015.
31. Hydrocortisone Valerate Cream [package insert]. Bronx NY: Perrigo May 2015.
32. Impoyz Cream [package insert]. San Antonio, TX: DPT Laboratories, Ltd.; November 2017.
33. Kenalog Spray [package insert]. San Antonio, TX: DPT Laboratories, Ltd.; May 2018
34. Locoid Cream [package insert]. Ferndale, MI: Ferndale Laboratories, Inc; October 2018.
35. Locoid Lipocream [package insert]. Ferndale, MI: Ferndale Laboratories, Inc; December 2018.
36. Luxiq Foam [package insert]. San Antonio, TX: DPT Laboratories, Ltd.; April 2018.
37. MiCort-HC Cream [package insert]. Ferndale, MI: Ferndale Laboratories, Inc; February 2016.
38. Mometasone Furoate Solution [package insert]. Allegan, MI: Perrigo; September 2015.
39. Olux Foam [package insert]. San Antonio, TX: DPT Laboratories, Ltd.; April 2018
40. Olux-E Foam [package insert]. San Antonio, TX: DPT Laboratories, Ltd.; May 2018

Section:	Prescription Drugs	Effective Date:	October 1, 2024
Subsection:	Topical Products	Original Policy Date:	January 1, 2020
Subject:	Topical Corticosteroids	Page:	23 of 24

41. Pandel Cream [package insert]. Melville, NY: PharmaDerm; January 2017.
42. Prednicarbate Cream [package insert]. Melville, NY: Fougera Pharmaceuticals Inc. October 2015
43. Psorcon Cream [package insert]. Hawthorne, NY: TaroPharma; May 2018.
44. Sernivo Spray [package insert]. San Antonio, TX: DPT Laboratories, Ltd.; February 2016
45. Synalar Cream [package insert]. Buena, NJ: Teligent Pharma, Inc.; November 2016. Solution; April 2017.
46. Synalar Ointment [package insert]. Buena, NJ: Teligent Pharma, Inc.; November 2016. Solution; April 2017.
47. Temovate Cream, Ointment [package insert]. Melville, NY: PharmaDerm January 2018
48. Texacort Solution [package insert]. San Antonio, TX: Mission Pharmacal Company, March 2012
49. Topicort Cream, Gel [package insert]. Hawthorne, NY: TaroPharma; September 2015.
50. Triamcinolone Acetonide Lotion [package insert]. Melville, NY: Fougera Pharmaceuticals, Inc; May 2015.
51. Trianex Ointment [package insert]. Farmville, NC: CMP Pharma, Inc; March 2017.
52. Tridesilon Cream [package insert]. Bronx, NY: Perrigo; June 2016.
53. Ultravate Lotion [package insert]. Jacksonville, FL: Ranbaxy; March 2018.
54. Vanos Cream [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; May 2017.
55. Verdeso Foam [package insert]. San Antonio, TX: DPT Laboratories, Ltd.; December 2017.
56. Westcort Ointment [package insert]. Jacksonville, FL: Ranbaxy; July 2009.
57. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; http://online.lexi.com/lco/action/index/dataset/complete_ashp [available with subscription]. Accessed March 2019.
58. Micromedex Solutions [database online]. Greenwood Village, CO: Truven Health Analytics Inc. Updated periodically. www.micromedexsolutions.com [available with subscription]. Accessed March 2019.
59. Atopic Dermatitis: Topical Corticosteroids Recommendations. <https://www.aad.org/practicecenter/quality/clinical-guidelines/atopic-dermatitis/topical-therapy/topical-corticosteroids-recommendations>. Accessed April 2021.
60. Eichenfield L, Tom W, Berger T, et al. Guidelines of Care for the Management of Atopic Dermatitis Section 2. Management and Treatment of Atopic Dermatitis with Topical Therapies. *J Am Acad Dermatol* 2014; 71:116-32. Accessed April 2021.
61. Menter A, Korman N, Elmetts C, et al. Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis. Section 3. Guidelines of Care for the Management and Treatment of Psoriasis with Topical therapies. *J Am Acad Dermatol* 2009; 60:643-59.
62. Burn Triage and Treatment - Thermal Injuries. Available at: <https://chemm.nlm.nih.gov/burns.htm>. Accessed April 2021.
63. Trianex. <https://cmppharma.com/trianex-0-05triamcinolone-acetonide-ointmentusp-now-available-from-promius-pharma-llc/>. Accessed April 2021.
64. Long CC, Finlay AY. The fingertip unit: a new practical measure. *Clin Exper Dermatol* 1991; 16: 444-446
65. Impeklo Lotion [package insert]. Morgantown, WV: Mylan Specialty, L.P.; May 2020.

Section:	Prescription Drugs	Effective Date:	October 1, 2024
Subsection:	Topical Products	Original Policy Date:	January 1, 2020
Subject:	Topical Corticosteroids	Page:	24 of 24

Policy History

Date	Action
December 2019	Addition to PA – QL established to limit foot bath use/waste
January 2020	Removed Duobrii, Bryhali, and Lexette from policy to add to Topical Products with Quantity Limits policy. Pre-PA quantity changed to 460/90 from 360/90
March 2020	Annual review
June 2020	Addition of Halog Solution
September 2020	Annual review
December 2020	Trianex and Vanos require formulary exception + PA
March 2021	Annual review
April 2021	Addition of Impeklo Lotion. Prior-authorization quantity limit increased to 720/90 from 460/90. Added requirement indicating it cannot be used in footbaths. Changed criteria to allow for renewals and changed approval duration to 6 months for both initiation and renewal
June 2021	Annual review
May 2022	Revised Pre-PA and PA quantity charts to allow patients to receive multiple corticosteroids up to the allowed limits
June 2022	Annual review. Removed fluocinonide 0.1% gel, ointment, and solution due to not being available in the market. Also removed halobetasol aerosol foam 0.05% as it is included in the Topical Products with Quantity Limits policy
September 2022	Annual review
September 2023	Annual review
September 2024	Annual review

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on September 6, 2024 and is effective on October 1, 2024.